fashion -WSS

fashion

author：fashion 2025-09-03 12:09:10 - browse：33183

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Why the advice to take all your antibiotics may be wrong

focus

WSS

EMA weighs against approval for Mirati's lung cancer drug

Close Medicare's dangerous gaps in addiction treatment coverage

Bird flu in milk supply is likely coming from asymptomatic cows

Why the advice to take all your antibiotics may be wrong

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

'The View' co

hotspot

fashion

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

'The View' co

Peter Hotez and the public health issue of online harassment

Key Senate committee drafts bipartisan bill to stem drug shortages

State Dept. review finds Biden bears some blame for Afghanistan failures

UnitedHealth financials solid despite Change Healthcare cyberattack

Hollywood unions extend contract negotiations for actors

A new deal aims to ramp up use of AI in rehab care decisions

23andMe had bad news about my health. I wish a person had delivered it

Prosecutors say FTX founder Sam Bankman

hotspot

Dogs on Prozac: What pet anti

Florida babysitter arrested over hot car death, authorities say

Hey, doctors: Don't be no

MultiPlan and major insurers sued for alleged medical price

Close Medicare's dangerous gaps in addiction treatment coverage

Exact Sciences stock tumbles despite strong cancer detection sales

explore

focus

focus

knowledge